8-K
filed January 11, 2024, 6:59 PM ET
ticker CATX
CIK 0000728387
other material
confidence high
sentiment positive
materiality 0.85
Perspective Therapeutics enters strategic agreements with Lantheus; $28M upfront, $33M equity investment possible
Perspective Therapeutics, Inc.
- Lantheus pays $28M upfront for exclusive option to license Pb212-VMT-α-NET (neuroendocrine tumors) and co-fund IND studies for PSMA/GRPR candidates.
- Lantheus to invest up to ~$33M for up to 19.9% equity (56.3M shares) at lower of $0.59/share or price in qualified $50M+ financing.
- Perspective to acquire Lantheus' Somerset, NJ radiopharmaceutical manufacturing facility for $8M cash, subject to regulatory approvals.
- Lantheus gets board observer, information rights, standstill, and right of first offer on M&A for 12 months.
- Closings of equity investment and asset purchase conditioned on Perspective raising at least $50M in qualified third-party financing.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Perspective Therapeutics, Inc. entered into Asset Purchase Agreement with Progenics Pharmaceuticals, Inc. valued at $8.0 million (effective 2024-01-08).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Progenics Pharmaceuticals, Inc.
- Value
- $8.0 million
- Effective
- 2024-01-08
Exact text from the filing
On January 8, 2024, the Company entered into that certain Asset Purchase Agreement (the “APA”) with Progenics Pharmaceuticals, Inc., a Delaware corporation (“Progenics”) and affiliate of Lantheus, pursuant to which the Company will acquire certain assets and the associated lease of Progenics’ radiopharmaceutical manufacturing facility in Somerset, New Jersey for a purchase price of $8.0 million in cash.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Perspective Therapeutics, Inc. entered into Option Agreement with Lantheus valued at $28.0 million (effective 2024-01-08).
- Action
- entry
- Agreement
- license
- Counterparty
- Lantheus
- Value
- $28.0 million
- Effective
- 2024-01-08
Exact text from the filing
On January 8, 2024, the Company entered into that certain Option Agreement (the “Option Agreement” and together with the Investment Agreement and the APA, the “Agreements”) with Lantheus whereby Lantheus was granted an exclusive option to negotiate an exclusive, worldwide, royalty- and milestone-bearing right and license to [ 212 Pb]VMT-α-NET, the Company’s clinical stage alpha therapy developed for the treatment of neuroendocrine tumors
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Perspective Therapeutics, Inc. entered into Investment Agreement with Lantheus Alpha Therapy, LLC valued at $33.2 million (effective 2024-01-08).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Lantheus Alpha Therapy, LLC
- Value
- $33.2 million
- Effective
- 2024-01-08
Exact text from the filing
On January 8, 2024, Perspective Therapeutics, Inc. (the “Company”) entered into that certain Investment Agreement (the “Investment Agreement”) with Lantheus Alpha Therapy, LLC, a Delaware limited liability company (“Lantheus”), pursuant to which the Company agreed to sell and issue to Lantheus in a private placement transaction (the “Private Placement”) certain shares (the “Shares”) of the Company’s common stock
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.